Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review.
Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review.
复制标题
DOI：
10.1016/j.survophthal.2015.04.003
复制
发表时间：
2015-11
影响因子：
5.1
通讯作者：
Ying H
中科院分区：
文献类型：
--
作者：
Kim M;Lee C;Payne R;Yue BY;Chang JH;Ying H
血管生成可能对青光眼构成临床挑战，例如在青光眼滤过手术后的伤口愈合阶段和称为新生血管性青光眼（NVG）的严重形式的继发性青光眼中。血管内皮生长因子（VEGF）是血管生成的关键介质，其上调发生在经历青光眼滤过手术以及NVG的眼睛中。这导致了研究抗VEGF治疗改善预后的能力，我们检查了他们关于抗VEGF药物（主要是贝伐单抗和雷珠单抗）在经历青光眼滤过手术或NVG的眼睛中的安全性和有效性的发现。联合常规治疗-如滤过手术后抗代谢药物和NVG中的全视网膜光凝-和抗VEGF药物可能会产生协同作用，尽管需要进一步研究来评估联合治疗的长期疗效。
Angiogenesis may pose a clinical challenge in glaucoma, for example during the wound healing phase after glaucoma filtration surgery and in a severe form of secondary glaucoma called neovascular glaucoma (NVG). Up regulation of vascular endothelial growth factor (VEGF), a key mediator of angiogenesis, occurs in eyes that have undergone glaucoma filtration surgery, as well as those with NVG. This has led to studies investigating the ability of anti-VEGF therapy to improve outcomes, and we examine their findings with respect to the safety and efficacy of anti-VEGF agents, mainly bevacizumab and ranibizumab, in eyes that have undergone glaucoma filtration surgery or have NVG. Combining conventional therapies—such as anti-metabolites after filtration surgery and panretinal photocoagulation in NVG—and anti-VEGF drugs may achieve a synergetic effect, although further studies are required to evaluate the long-term efficacy of combination treatments.